You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Dynasore Analogues for Ocular Surface Protection
SBC: MEDCHEM PARTNERS LLC Topic: NEI7. PROJECT SUMMARY Diseases of the ocular surface are among the top reasons for visits to eye care practitioners. These conditions can severely affect eyesight and quality of life. Symptoms may include blurry vision, discomfort or pain, redness and itching, and in severe cases, blindness due to corneal scarring. Many ocular surface diseases are initiated by loss of tear film homeostasis and can be ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Science Take-Out Kits for Improving Environmental Health Literacy on Vaping
SBC: Science Take-Out, LLC Topic: RABSTRACT This supplement project will expand on our current STTR Phase I project in which we partnered with University of Rochesterandapos;s Environmental Health Sciences Center to develop three Science Take-Out vaping education kits. Our vaping education kits involve students in using hands-on activities and real-life scenarios to investigate the harmful effects of chemicals used in e-cigarette f ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDFiloviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction
SBC: IMMUNOCHEM THERAPEUTICS LLC Topic: 102PROJECT SUMMARY Cognitive decline and deterioration of long term cognitive performance are major side effects of CNS cancer treatmentBrain metastases are the most common CNS malignancies and a common cause of morbidity and mortality in aboutof all cancer patients with systemic diseaseaffecting overpatients in the US annuallyAs most systemic chemotherapy agents do not cross the blood brain barriert ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Custom-Fit Personal Sound Amplification Smartphone Application
SBC: ASCENDING HEARING TECHNOLOGIES, LLC Topic: NIDCDPROJECT SUMMARYPersonal sound amplification productsPSAPshave recently become available to the publicPSAPs serve a potentially important role in providing audibility of sounds for adults who have difficulty hearing in some daily living situationsbut may not be candidates for traditionalhigh amplification hearing aidsFewer thanof adults with hearing loss reporting use of hearing aidsciting high cos ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A novel asthma drug candidate targeting the GABAergic system in lung inflammation
SBC: PANTHERICS INCORPORATED Topic: NHLBIThe proposed research will advance preclinical characterization and validation of a novel drug for asthmaA growing body of research has uncovered functional gamma amino butyric acid type A receptorGABAARsignaling in non neuronal cellsOur research has demonstrated that ligands activating GABAAR subtypes located on airway smooth muscle and immune cells reduce airway hyper responsivenessAHRand inflam ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infants
SBC: 149 MEDICAL INC Topic: 103PROJECT SUMMARY ABSTRACT Every year in the United States aboutof theinfants born extremely prematureandltweeks gestational age and andltg birth weightELGAdevelop intraventricular hemorrhageIVHIVH is associated with high risk for cerebral palsy and significant intellectual disabilitycausing lifelong implications for affected children and their families and considerable economic burdenIVH is caused ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Improving ALS Diagnosis using Needle I-EMG
SBC: Haystack Diagnostics, Inc. Topic: 103PROJECT SUMMARY Needle electromyographyEMGremains the standard approach for assessing neuromuscular diseaseWhile the technique has proven to be clinically valuable over the lastyearsit has important limitationsThese include its not being sensitive to alterations in muscle composition and structureits inability to assess the contractile apparatus of muscleand its subjective nature with an inter rat ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Medications for Synthetic Cannabinoid Abuse
SBC: PAFOSPharma, LLC Topic: R41PROJECT SUMMARY ABSTRACT In response to PAthis Phase I STTR proposal will aim at developing pharmacotherapies that can act aslife savermedications to counteract the neurotoxic effects of synthetic cannabinoidsSCsTowards this goalwe will synthesize CB R antagonists with fast onsets of action that can be administered in an emergency roomERsituationThe rationale is based on the successful soft agonis ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Multi-Modal Mechanisms of Novel Sulfated Non Anticoagulant Heparin inSickle Cell Disease Management
SBC: VASCULAR VISION PHARMACEUTICAL CO Topic: NHLBIAbstractThe pathogenesis of Sickle cell diseaseSCDcomprises a complex interplay of factors associated with vascular endothelial activationintense inflammationand increased sickle cell adhesionMicrovascular occlusion in SCD is initiated by adhesion of sickle red blood cellsRBCsto the endotheliumleading to acute painful vasoocclusive crisisVOCand the clinical morbidity in SCDTreatment strategies inc ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health